Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Acquisitions & Divestments: 2024-2025

Historic Change in Acquisitions & Divestments for Immunome (IMNM) over the last 1 years, with Sep 2025 value amounting to $125.0 million.

  • Immunome's Change in Acquisitions & Divestments rose 316.67% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.0 million, marking a year-over-year change of. This contributed to the annual value of $155.0 million for FY2024, which is N/A change from last year.
  • Per Immunome's latest filing, its Change in Acquisitions & Divestments stood at $125.0 million for Q3 2025, which was up 108.33% from $60.0 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Acquisitions & Divestments peaked at $125.0 million during Q3 2025, and registered a low of $15.0 million during Q1 2025.
  • For the 2-year period, Immunome's Change in Acquisitions & Divestments averaged around $63.0 million, with its median value being $60.0 million (2025).
  • Data for Immunome's Change in Acquisitions & Divestments shows a peak YoY skyrocketed of 316.67% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Immunome's Change in Acquisitions & Divestments stood at $85.0 million in 2024, then surged by 316.67% to $125.0 million in 2025.
  • Its last three reported values are $125.0 million in Q3 2025, $60.0 million for Q2 2025, and $15.0 million during Q1 2025.